AGIOS PHARMACEUTICALS INC's ticker is AGIO and the CUSIP is 00847X104. A total of 147 filers reported holding AGIOS PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is 1.39 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $1,174,005 | +66.4% | 41,455 | +34.9% | 0.01% | +66.7% |
| Q1 2023 | $705,615 | -52.0% | 30,719 | -41.3% | 0.00% | -70.0% |
| Q4 2022 | $1,469,033 | -99.6% | 52,316 | +294.1% | 0.01% | +233.3% |
| Q3 2022 | $375,388,000 | -68.7% | 13,274 | -61.2% | 0.00% | -80.0% |
| Q3 2020 | $1,198,190,000 | +60.7% | 34,234 | +145.6% | 0.02% | +25.0% |
| Q2 2020 | $745,564,000 | +156860.8% | 13,941 | +4.0% | 0.01% | +71.4% |
| Q1 2020 | $475,000 | -43.8% | 13,400 | -24.3% | 0.01% | 0.0% |
| Q4 2019 | $845,000 | +59.1% | 17,705 | +8.1% | 0.01% | +40.0% |
| Q3 2019 | $531,000 | -89.7% | 16,374 | -81.4% | 0.01% | -88.4% |
| Q1 2017 | $5,150,000 | +2.1% | 88,185 | -7.7% | 0.04% | -6.5% |
| Q3 2016 | $5,045,000 | +303.6% | 95,510 | +220.0% | 0.05% | +283.3% |
| Q2 2016 | $1,250,000 | -82.5% | 29,847 | -70.5% | 0.01% | -85.0% |
| Q3 2015 | $7,151,000 | +215.3% | 101,299 | +396.3% | 0.08% | +175.9% |
| Q2 2015 | $2,268,000 | – | 20,411 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Eagle Health Investments LP | 431,413 | $12,558,000 | 3.09% |
| Casdin Capital, LLC | 2,090,000 | $60,840,000 | 2.73% |
| Rock Springs Capital Management LP | 2,665,275 | $77,586,000 | 1.95% |
| Bellevue Group AG | 4,129,292 | $120,204,000 | 1.40% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,177,374 | $34,273,000 | 1.05% |
| Altium Capital Management LP | 66,196 | $1,927,000 | 0.64% |
| ArrowMark Colorado Holdings LLC | 1,295,948 | $37,725,000 | 0.33% |
| FARALLON CAPITAL MANAGEMENT LLC | 1,333,012 | $38,804,000 | 0.19% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 21,500 | $707,000 | 0.16% |
| Virtus ETF Advisers LLC | 11,541 | $336,000 | 0.15% |